30 likes | 201 Views
Kim et al._Fig. S1. A. Thymus. B. Gated on CD4 - CD8 - subset. PIDD +/+. PIDD -/-. CD44. CD8. CD4. CD25. C. BM. CD43. IgM. B220. D. E. Spleen. LN. counts. CD4. B220. CD8. Spleen. F. IgD. B220. IgM. Kim et al._Fig. S2. 1800 1600 1400 1200 1000 800 600 400
E N D
Kim et al._Fig. S1. A. Thymus B. Gated on CD4-CD8- subset PIDD +/+ PIDD -/- CD44 CD8 CD4 CD25 C. BM CD43 IgM B220 D. E. Spleen LN counts CD4 B220 CD8 Spleen F. IgD B220 IgM
Kim et al._Fig. S2. 1800 1600 1400 1200 1000 800 600 400 200 0 Caspase-2 activity (RFU) No Tx Etoposide Etoposide Etoposide + VDVAD-CHO + DEVD-CHO 2000 1500 1000 500 0 Caspase-9 activity (RFU) No Tx EtoposideEtoposide + LEHD-CHO 50000 40000 30000 20000 10000 0 Caspase-3 activity (RFU) No Tx γ-IR γ-IR + DEVD-CHO
Supplementary Figure Legends: Fig. S1 Normal development of lymphocyte subsets in PIDD-deficient mice. Flow cytometric immunophenotyping of various immune sub-populations in (A)-(B) thymus, (C) bone-marrow (BM), (D) lymph-nodes (LN), and (E)-(F) spleen from PIDD+/+ and PIDD-/- mice. Numbers in each quadrant indicate the percentage of the cells. Results are representative of ≥3 independent experiments. Fig. S2 Absence of PIDD does not alter caspase activation in thymocytes. Caspase activities were quantified in the wild-type and PIDD-deficient thymocytes treated with either etoposide (for caspase-2 and -9 activities) or gamma-irradiation (for caspase-3 activity) with or without the following caspase inhibitors: VDVAD-CHO, caspase-2; DEVD-CHO, caspase-3; LEHD-CHO, caspase-9. Caspase inhibitors were added immediately prior to the assay according to the manufacturer’s instruction). RFU=Relative fluorescent units.